At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
lasmiditan 200 mgdrug
Likely dose
lasmiditan 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Multicenter, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Oral Lasmiditan in Subjects With Normal and Impaired Hepatic Function
In Brief
A Phase 1 clinical trial evaluating lasmiditan 200 mg for Migraine. Completed, enrolled 24 participants across 3 sites in 2 countries.
Detailed Summary
This is a multicenter, open-label, non-randomized, parallel-group, single dose study. This study will enroll up to 24 participants and will include 2 hepatic impaired participant groups and one group of control participants with normal hepatic function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesCanada, United States
CollaboratorsAlgorithme Pharma Inc, CoLucid Pharmaceuticals
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartMar 2017
Primary CompletionJul 2017
TodayJul 2026
First PostedFeb 2, 2017
Enrollment StartMar 14, 2017
Primary CompletionJul 17, 2017
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 9.4 years ago
Interventions
lasmiditan 200 mgdrug
single dose